Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-12-04
2010-12-14
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S159100, C530S387300, C530S389400
Reexamination Certificate
active
07850965
ABSTRACT:
Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful VHand VLpairs useful when preparing the polyclonal antibody.
REFERENCES:
patent: 6451309 (2002-09-01), Hooper et al.
patent: 6562376 (2003-05-01), Hooper et al.
patent: 6783759 (2004-08-01), Rosengard
patent: 2005/0129700 (2005-06-01), Rosengard
patent: 2006/0275766 (2006-12-01), Haurum et al.
patent: 2007/0141048 (2007-06-01), Oleksiewicz et al.
patent: WO 03/049117 (2003-06-01), None
patent: WO 03/068151 (2003-08-01), None
patent: WO 2004/061104 (2004-07-01), None
patent: WO 2004/061107 (2004-07-01), None
patent: WO 2005/042774 (2005-05-01), None
patent: WO 2006/007850 (2006-01-01), None
patent: WO 2006/007853 (2006-01-01), None
patent: WO 2007/101441 (2007-09-01), None
Lustig, et al. Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge. J. Virol. 2005; 79(21):13454-13462.
Bregenholt and Haurum Pathogen-specific recombinant human polyclonai antibodies: biodefence application. Expert Opin. Biol Ther. 2004; 4(3):387-396.
Fogg, et al. Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virion. J. Virol. 2004; 78(19):10230-10237.
Isaacs, et al. Restoration of Complement-Enhanced Neutralization of Vaccinia Virus Virions by Novel Monoclonal Antibodies Raised against the Vaccinia Virus Complement Control Protein. J Virol. 2003; 77(15): 8256-8262.
Schmaljohn, et al. Production and Characterization of Human Monoclonal Antibody Fab Fragments to Vaccinia Virus from a Phage-Display Combinatorial Library. Virol. 1999; 258:189-200.
Watts and Lanzavecchia. Suppressive Effect of Antibody on Processing of T Cell Epitopes. J. Exp. Med. 1993; 178:1459-1463.
Nowak, MA.Immune responses against multiple epitopes: a theory for immunodominance and antigenic variation. Sem. Virol. 1996. 7:83-92.
Schmaljohn, C., et al., “Production and Characterization of Human Monoclonal Antibody Fab Fragments to Vaccinia Virus from a Phage-Display Combinatorial Library,”Virology 258:189-200, Academic Press (1999).
Boulter, E.A., and Appleyard, G., “Differences between Extracellular and Intracellular Forms of Poxvirus and Their Implications,”Prog. Med. Virol. 16:86-108, Karger (1973).
Chen, N., et al., “Virulence differences between monkeypox virus isolates from West Africa and the Congo basin,”Virology 340:46-63, Academic Press (Sep. 2005).
Davies, D.H., et al., “Profiling the humoral immune response to infection by using proteome microarrays: High-throughput vaccine and diagnostic antigen discovery,”Proc. Natl. Acad. Sci. U.S.A. 102:547-552, The National Academy of Sciences (Jan. 2005).
Demkowicz, W.E., et al., “Identification and Characterization of Vaccinia Virus Genes Encoding Proteins That are Highly Antigenic in Animals and Are Immunodominant in Vaccinated Humans,”J. Virol. 66: 386-398, American Society for Microbiology (1992).
Fogg, C., et al., “Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions,”J. Virol. 78:10230-10237, American Society for Microbiology (Oct. 2004).
Galmiche, M.C., et al., “Neutralizing and Protective Antibodies Directed against Vaccinia Virus Envelope Antigens,”Virology 254:71-80, Academic Press (1999).
Gordon, J., et al., “A Prominent Antigenic Surface Polypeptide Involved in the Biogenesis and Function of the Vaccinia Virus Envelope,”Virology 18:671-686, Academic Press, Inc. (1991).
Hooper, J.W., et al., “DNA Vaccination with Vaccinia Virus L1R and A33R Genes Protects Mice against a lethal Poxvirus Challenge,”Virology 266:329-339 (2000).
Hooper, J.W., et al., “Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates,”Virology 306:181-195, Elsevier Science (2003).
Issacs, S.N., et al., “Restoration of Complement-Enhanced Neutralization of Vaccinia Virus Virions by Novel Monoclonal Antibodies Raised against the Vaccinia Virus Complement Control Protein,”J. Virol. 77:8256-8262, American Society for Microbiology (2003).
Lai, C., et al., “The Purified 14-Kilodalton Envelope Protein of Vaccinia Virus Produced inEscherichia coliInduces Virus Immunity in Animals,”J. Virol. 65:5631-5635, American Society for Microbiology (1991).
Law, M., and Smith, G.L., “Antibody Neutralization of the Extracellular Enveloped Form of Vaccinia Virus,”Virology 280:132-142, Academic Press (2001).
Lin, C-L., et al., “Vaccinia Virus Envelope H3L Protein Binds to Cell Surface Heparan Sulfate and Is Important for Intracellular Mature Virion Morphogenesis and Virus Infection In Vitro and In Vivo,”J. Virol. 74:3353-3365, American Society for Microbiology (2000).
Lustig, S., et al., “Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge,”J. Virol. 79:13454-13462, American Society for Microbiology (Nov. 2005).
Mullick, J., et al., “Herpes and pox viral complement control proteins: ‘the mask of self’,”Trend Immunol. 24:500-507, Elsevier Ltd. (2003).
Ramirez, J.C., et al., “Administration to mice of monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions,”J. Gen. Virol. 83:1059-1067, Society for General Microbiology (2002).
Rodriguez, J.F., et al., “Isolation and Characterization of Neutralizing Monoclonal Antibodies of Vaccinia Virus,”J. Virol. 56:482-488, American Society for Microbiology (1985).
Wallengren, K., et al., “The A17L Gene Product of Vaccinia Virus Is Exposed on the Surface of IMV,”Virology 290:143-152, Academic Press (2001).
Wolffe, E.J., et al., “A Myristylated Membrane Protein Encoded by the Vaccinia Virus L1R Open Reading Frame Is the Target of Potent Neutralizing Monoclonal Antibodies,”Virology 21:53-63, Academic Press, Inc. (1995).
Dialog English abstract for WO 2004-061107 A1, 2 pages, accessed on May 2007 (Document FP3 listed on accompanying PTO/SB/08A).
Law, M., et al., “An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model,”J. Gen. Virol. 86:991-1000, SGM (Apr. 2005).
Co-pending U.S. Appl. No. 11/632,937, inventors Rasmussen, S.K., et al., filed Jan. 19, 2007 (Not Published).
Co-pending U.S. Appl. No. 11/658,201, inventors Rasmussen, L.K., et al., filed Jan. 22, 2007 (Not Published).
Co-pending U.S. Appl. No. 11/792,927, inventors Lantto, J., et al., filed Jun. 13, 2007 (Not Published).
Co-pending U.S. Appl. No. 11/658,021, inventors Rasmussen, L.K., et al., filed Jan. 22, 2007 (Not Published).
Gordon, J., et al., “A Prominent Antigenic Surface Polypeptide Involved in the Biogenesis and Function of the Vaccinia Virus Envelope,”Virology 181:671-686, Academic Press, Inc. (1991).
Bregenholt, S., and Haurum, J., “Pathogen-specific recombinant human polyclonal antibodies: biodefence applications,”Expert Opin. Biol. Ther. 4:387-396, Ashley Publications Ltd. (Mar. 2004).
Haurum, J., and Bregenholt, S., “Recombinant polyclonal antibodies: Therapeutic antibody technologies come full cir
Hansen Margit Haahr
Jensen Allan
Lantto Johan
Rasmussen Lone Kjær
Rasmussen Søren Kofoed
Mosher Mary E
Snyder Stuart W
Sterne Kessler Goldstein & Fox P.L.L.C.
Symphogen A/S
LandOfFree
Anti-orthopoxvirus recombinant polyclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-orthopoxvirus recombinant polyclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-orthopoxvirus recombinant polyclonal antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181916